Legend Biotech Jumps 42% On New Data -- Here's What Comes Next

2026-06-03 08:32:46 ET

Legend Biotech overview

My upside case here remains intact, and I’m still buy-rated on Legend Biotech Corporation ( LEGN ), since the story is increasingly showing us a pretty clear earlier-is-better shift for Carvykti. In my previous coverage , I went into details of Carvykti from a sales perspective, but this week, we got some new data which I feel consistently shows that moving CAR-T into the 2nd-line setting can materially improve outcomes versus later use. Progression-free and overall survival were meaningfully extended in CARTITUDE-4 relative to CARTITUDE-1, albeit in different patient populations, and alongside this, we saw a step-function improvement in safety, such as Parkinsonism rates falling from mid-single digits in late-line settings to less than 1% earlier. Operationally speaking, here, this earlier use also drives a 99% manufacturing success rate, which goes to show fitter T-cells and lower disease burden in these settings. This is a plus for both efficacy and reliability....

Read the full article on Seeking Alpha

For further details see: